600 patients66,869 observations120 daysLIVE
← Patients

Patient P-01822

Synthetic patientNBL-101 · Day 99 · 65–74 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 started — Baseline state S14
  2. Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • Treatment adherence+8
  • Toxicity-8
  • GI instability-5
  • Inflammatory activity-4
  • Nutritional resilience-2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    92%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days
    View similar patientsSimulateAdd to intervention cohortAll evidence

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    70.6/100
    stable · +0.8 vs previous 14 d
    Toxicity
    Blood
    47.8/100
    improving · -3.9 vs previous 14 d
    Sleep quality
    Wearable
    1.7/100
    improving · +0.8 vs previous 14 d
    Energy level
    Daily log
    1.1/10
    worsening · -0.1 vs previous 14 d
    Stress level
    Daily log
    8.4/10
    stable · -0.0 vs previous 14 d
    Steps
    Wearable
    5,287
    stable · -110 vs previous 14 d
    Adherence
    Companion
    46.8 %
    worsening · -9.6 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 17 from the failing basin, 77 from restoration.

    Would help
    • GI-04 GI Support Protocol
      73% improved among 124 similar · onset 8 d · confidence 97%
    • ME-01 Monitoring Escalation
      100% improved among 77 similar · onset 3 d · confidence 80%
    • NP-02 Dietary Support Protocol
      63% improved among 64 similar · onset 10 d · confidence 80%
    Would not help
    • Keep fat low
      GI +4.5 next day on high-intake days · n 26
    • Keep simple carbs low
      GI +3.3 next day on high-intake days · n 18
    • Keep fibre low
      GI +2.9 next day on high-intake days · n 23
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Dietary fat load
      +4.5detractor · 95%
    • Simple carbohydrates
      +3.3detractor · 95%
    • Insoluble fibre
      +2.9detractor · 69%
    • Alcohol
      -2.4no signal · 49%
    • Histamine load
      +1.4no signal · 35%
    • Spicy / capsaicin
      -0.2no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production ↓80
      • MicrobiomeButyrate capacity 37/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Drug metabolism and exposure ↑60
      • DNACYP2D6 poor metabolizer → higher exposure
      • BloodToxicity index 48
    • Inflammatory signalling ↓40
      • BloodInflammatory load index 61
      • WearableHRV 18 ms, trending down
    • Mucosal barrier integrity ↓30
      • Daily logGI symptom score 71 and rising
      • WearableSleep 5.0 h, below personal baseline
    • Autonomic recovery ↑20
      • WearableShort sleep window
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    Microbiome
    Shannon diversity 2.1 · butyrate capacity 37/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    16 ms
    Sleep
    5.1 h
    Steps
    5,180
    Resting HR
    73 bpm
    Daily log: GI score 71, nutritional resilience 29, adherence 47.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0181344%S01NP-02no change40
    P-0132735%S01GI-04improved56
    P-0168832%S01GI-04improved40
    P-0131029%S01——57
    P-0187726%S01CR-01improved67
    P-0160418%S01——71
    P-0145233%S02GI-04improved46
    P-0163531%S02GI-04improved49
    P-0145926%S02——51
    P-0149818%S02——56
    P-0149918%S02——65
    P-0173640%S03ME-01improved46